Post-menopausal Osteoporosis Clinical Trial
Official title:
A 2-year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care.
Verified date | March 2018 |
Source | Sheffield Teaching Hospitals NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study to determine if the three licensed bisphosphonates (alendronate, ibandronate and risedronate):a) affect the peripheral skeleton differently, as assessed by quantitative ultrasound of bone (QUS), peripheral quantitative computed tomography (pQCT) and dual−energy x−ray absorptiometry (DXA)? b) have different effects on bone cells and their activity as assessed by flow cytometry and biochemical markers of bone cell activity? The aim of the study is to compare the effects of three licensed bisphosphonates on bone quantity and quality. There has been no such study before. Most of the measures of bone quantity and quality used in this protocol have not been studied with any of these three agents. The novelty of the study necessitates the establishment of reference ranges and this explains the need for the inclusion of a group of young women.
Status | Completed |
Enrollment | 410 |
Est. completion date | December 2014 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 35 Years to 85 Years |
Eligibility |
Inclusion Criteria: - be female - at least 5 years post menopausal but <85 years - BMD T-score (at the lumbar spine or total hip) of less than or equal to - 2.5, or T-score less than or equal to -1 with a low trauma fracture. - be ambulatory - be able and willing to participate in the study and provide written informed consent Exclusion Criteria: - have evidence of a clinically significant organic disease which could prevent the patient from completing the study - have a BMI less than 18 or greater than 35 - abuse alcohol or use illicit drugs or who consumed more than 4 servings of any alcoholic beverage one day prior to the visit (i.e., subjects who might be binge drinkers) - have any history of cancer within the past 5 years excluding skin cancer non melanomas - have a history of ongoing conditions or diseases known to cause abnormalities of calcium metabolism or skeletal health (secondary osteoporosis) - Chronic renal disease (as defined by a creatinine clearance of = 30ml/min) - Acute or chronic hepatic disease - Malabsorption syndromes - Hyperthyroidism as manifested by TSH outside the lower limit of the normal range - Hyperparathyroidism - Hypocalcemia or hypercalcemia - Osteomalacia - Cushing's syndrome - Patient who are currently on glucocorticoid therapy - have a serum calcium less than 2.2 mmol/l and a PTH above 75ng/l - have a history of any known condition that would interfere with the assessment of DXA at either lumbar spine or femoral neck - have markedly abnormal clinical laboratory parameters that are assessed as clinically significant by the investigator - use any of the following medications within 12 months of starting study drug - Bisphosphonates (at any dose) - Use of any fluoride with the exception use for oral hygiene - Strontium - Other bone agents (i.e., SERM, isoflavones, HRT etc) - have participated in another clinical trial involving active therapy 3 months prior to randomisation - have a history of allergic reaction to bisphosphonates - patient taking calcium supplements within the last month prior to randomisation - We will exclude patients with secondary osteoporosis, those who have been on anti-resorptive treatments in the past year, and women less than 5 years since menopause, and those with bilateral fractures in the measurement regions (heel, hip and forearm). - Have suffered a recent fracture within the last 12 months |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Academic Unit of Bone Metabolism (Sheffield) | Sheffield | South Yorkshire |
Lead Sponsor | Collaborator |
---|---|
Sheffield Teaching Hospitals NHS Foundation Trust | Procter and Gamble, University of Sheffield |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in heel broadband ultrasound attenuation | 2 years | ||
Secondary | Changes in the percentage of MCSFR+ monocytes in the peripheral blood at baseline and after one week and 48 weeks of therapy | 2 years | ||
Secondary | Change in SOS at finger and heel at 48 weeks. | 2 years | ||
Secondary | Change in lumbar spine and total hip BMD measured by DXA at 48 weeks | 2 years | ||
Secondary | Change in finger BMD measured by RA at 48 weeks | 2 years | ||
Secondary | Change in heel BMD measured by DXL at 48 weeks | 2 years | ||
Secondary | Change in distal tibia and ultradistal forearm cortical and trabecular volumetric BMD by pQCT at 48 weeks | 2 years | ||
Secondary | Changes in cathepsin K and MM enzyme and OPG and RANK-L protein at 12 weeks | 12 weeks | ||
Secondary | Changes in uNTX and uCTX. At 12 weeks | 12 weeks | ||
Secondary | Change in disulfide bond content of nails at 48 weeks | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01224717 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
|
Phase 1 | |
Completed |
NCT00551174 -
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
|
Phase 4 | |
Completed |
NCT00984893 -
Intra-venous Zoledronic Acid Once Yearly
|
N/A | |
Withdrawn |
NCT01826656 -
Bone Healing in Healthy and Post-menopausal Osteoporotic Women
|
N/A | |
Completed |
NCT00718861 -
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
|
Phase 3 | |
Completed |
NCT00081653 -
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
|
Phase 4 | |
Completed |
NCT00503113 -
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
|
Phase 4 | |
Completed |
NCT00150969 -
Vitamin K Supplementation in Post-Menopausal Osteopenia
|
Phase 3 | |
Completed |
NCT03432533 -
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
|
Phase 3 | |
Completed |
NCT00545779 -
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
|
Phase 4 | |
Completed |
NCT00533650 -
Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)
|
Phase 2 | |
Active, not recruiting |
NCT01232647 -
Vitamin K as Additive Treatment in Osteoporosis
|
Phase 2/Phase 3 |